Herbs (Global Traditional) · Native American
Purple Coneflower (Echinacea purpurea) (Echinacea purpurea)
Strong Evidencebotanical
Hermetica Superfood Encyclopedia
Echinacea purpurea is a flowering plant containing bioactive compounds like alkylamides and polyphenols that modulate immune function. Clinical studies demonstrate it can reduce the incidence of upper respiratory infections by 19% and shorten infection duration in children.
Echinacea purpurea is a perennial flowering plant native to North America, belonging to the Asteraceae (daisy) family. The herb is extracted from various plant parts including roots, leaves, and flowers, and is available in multiple forms such as standardized extracts, capsules, and fluid preparations.
The largest clinical trial from Cardiff University involved 755 screened subjects (673 completed) over 4 months, finding significant therapeutic benefits for cold prevention. A meta-analysis of 9 RCTs (1,518 treatment participants) found Echinacea purpurea reduced URTI duration, incidence, and antibiotic usage in children. However, acute treatment studies showed no significant benefit over placebo.
Fluid extract: 4 mL twice daily has been studied. The major prophylaxis trial used Echinaforce extract over 4 months, though specific dosing was not provided in available abstracts. Products vary widely in standardization and plant parts used. Consult a healthcare provider before starting any new supplement.
Purple Coneflower (Echinacea purpurea) is not consumed as a food for macronutrient value; it is used primarily as a medicinal herb. Its therapeutic profile is defined by its bioactive phytochemical constituents rather than caloric or macronutrient content. Key bioactive compounds include: • **Alkamides (Alkylamides):** ~0.01–0.04% in dried root, ~0.001–0.01% in aerial parts; the most bioavailable immunomodulatory compounds, rapidly absorbed through oral mucosa and GI tract with high oral bioavailability (~50–75%); key compounds include dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides. • **Caffeic acid derivatives:** Cichoric acid (dicaffeoyltartaric acid) is the dominant phenolic, present at ~1.2–3.1% of dry weight in aerial parts and ~0.6–2.1% in roots; echinacoside (caffeic acid glycoside) at ~0.3–1.3% in roots (more abundant in E. angustifolia); caftaric acid at ~0.1–0.8%; chlorogenic acid at ~0.02–0.1%. Bioavailability of cichoric acid is moderate but subject to rapid enzymatic degradation. • **Polysaccharides:** Arabinogalactans and heteroxylans at ~1–4% of dry root weight; fucogalactoxyloglucans in aerial parts; these high-molecular-weight immunostimulating compounds have low oral bioavailability but may exert effects through gut-associated lymphoid tissue (GALT) and Peyer's patches. • **Glycoproteins:** ~1–2% of dry weight, containing arabinose-rich carbohydrate moieties; contribute to macrophage activation. • **Polyacetylenes:** Including pontica epoxide and other C13 acetylenic compounds at trace levels (~0.001–0.01%); found primarily in roots; some show antifungal and anti-inflammatory activity. • **Flavonoids:** Rutoside (rutin), quercetin, and kaempferol glycosides present at ~0.1–0.5% of aerial parts; contribute antioxidant capacity. • **Essential oil (volatile compounds):** ~0.05–0.3% of aerial parts; contains borneol, bornyl acetate, germacrene D, caryophyllene, and humulene. • **Minerals (in dried herb):** Potassium ~15–20 mg/g, calcium ~8–12 mg/g, magnesium ~2–4 mg/g, iron ~0.1–0.5 mg/g, zinc ~0.02–0.06 mg/g, selenium trace amounts. • **Vitamins:** Trace amounts of vitamin C (~2–5 mg/100g dried herb), small amounts of B-vitamins; not a significant dietary source. • **Fiber:** Crude fiber ~15–25% of dried aerial parts (not typically relevant as it is consumed as tea or extract, not bulk plant material). • **Protein:** ~10–15% crude protein in dried aerial parts (not consumed in nutritionally relevant quantities). • **Bioavailability notes:** Alkamides are the most pharmacokinetically favorable compounds, detectable in plasma within 20 minutes of oral dosing, with peak levels at ~30–60 minutes. Cichoric acid shows lower systemic bioavailability due to esterase degradation but is partially absorbed intact. Polysaccharides are largely not absorbed systemically but interact with immune cells in the gut mucosa. Ethanolic extracts preferentially concentrate alkamides and caffeic acid derivatives, while aqueous extracts (teas) favor polysaccharides and glycoproteins. Standardized commercial preparations typically guarantee alkamide content (≥0.25 mg/mL) and/or cichoric acid content (≥2.5 mg/mL) for quality assurance.
Echinacea's alkylamides and phenolic compounds activate macrophages and enhance natural killer cell activity through modulation of cytokine production. The compounds stimulate phagocytosis and increase production of interferon-α, interleukin-1β, and tumor necrosis factor-α. Polysaccharides in echinacea bind to complement receptors and activate the alternative complement pathway.
A meta-analysis of 9 randomized controlled trials found preventive echinacea use reduced upper respiratory tract infection incidence by 19%. Another systematic review demonstrated significant reduction in infection duration in children (SMD = -0.19). Studies show reduced antibiotic usage when echinacea is used for respiratory infections. Most trials used standardized extracts containing 4% phenolics for 8-12 weeks.
Echinacea is generally well-tolerated with mild gastrointestinal upset being the most common side effect. It may interact with immunosuppressive medications like cyclosporine by counteracting their effects. Individuals with autoimmune conditions should use caution as echinacea may stimulate immune activity. Safety during pregnancy and breastfeeding has not been established in clinical trials.
